ATHEROSCLEROTIC DISEASE IS the primary cause of cardiovascular morbidity and mortality in North America. The atherogenic process is progressive and multifactorial. It can be regulated, at least in part, by lifestyle choices, including diet. Dietary choices, including the amount and type of fats commonly consumed, have been shown to impact atherosclerotic development. For example, a high intake of dietary cholesterol will elevate circulating cholesterol levels, which are associated with the development of atherosclerosis and increased cardiovascular risk. In addition, several epidemiological and interventional investigations have revealed a significant positive association between coronary heart disease and the consumption of trans fatty acids (TFA) from industrially hydrogenated vegetable sources (iTFA) (11, 47, 48) . TFA intake has been associated with atherogenic risk factors, such as elevated plasma cholesterol and triglyceride (TG) levels and plasma markers of inflammation and endothelial dysfunction (24, 42) . Elaidic acid (18:1t9), one of the main TFA isomers formed during the commercial hydrogenation of vegetable oils, is known to accumulate in atherosclerotic lesions and adipose tissue and is associated with increased risk of coronary heart disease (14, 41) . Our laboratory has recently shown that TFA from a hydrogenated vegetable shortening source dose-dependently initiates the atherogenic process, an event not normally observed in the LDL receptor-deficient (LDLr Ϫ/Ϫ ) mouse, unless it is fed a strongly atherogenic diet (6) . As a result of the multiple adverse effects reported due to elevated TFA intake, numerous agencies and governing bodies in North America and Europe recommend limiting TFAs in the diet and have mandated regulations regarding TFA levels in the food supply (3, 18, 23, 29) .
With mounting evidence for the atherogenic actions of TFA, it becomes increasingly important to identify approaches to reduce the deleterious effects of dietary TFAs. Increasing the consumption of omega-3 (-3) fatty acids has been suggested as one dietary strategy to provide cardioprotection against atherosclerotic disease (17, 22) . Flaxseed (Linum usitatissimum) is one of the richest plant sources of the -3 polyunsaturated fatty acid (PUFA) ␣-linolenic acid (ALA; C18:3n-3). ALA demonstrates significant cardioprotective effects (12, 13, 19) . ALA can also be converted in the body to the cardioprotective -3 PUFAs found in fish oils, eicosapentaenoic acid (EPA), and docosahexaenoic acid. Flaxseed is also a good source of two other nutrients that contribute to the cardioprotective effects of flaxseed: dietary fiber and phytoestrogens called lignans. Whole ground flaxseed or the derivatized components of flaxseed have been shown to prevent atherosclerotic development under various conditions and in multiple animal models (15, 16, 25, 33-36, 38, 40) . Dietary flaxseed has also exhibited beneficial effects in clinical studies on risk factors commonly associated with cardiovascular disease (7, 21, 26, 32, 38) .
Our aim was to determine whether consuming a dietary agent with demonstrated anti-atherogenic effects can protect against atherosclerotic development in the presence of a known atherogenic agent. To do so, we examined the effects of consuming dietary flaxseed or one of its fractions on atherosclerotic plaque formation in the presence of iTFAs and/or dietary cholesterol in the LDLr Ϫ/Ϫ mouse. We hypothesized that consuming dietary flaxseed would prevent atherosclerotic development induced by both dietary cholesterol and iTFAs.
METHODS

Animals and dietary interventions.
One hundred forty (140) female C57BL/6J LDL receptor-deficient mice (Jackson Laboratory, Bar Harbor, ME), 5-7 wk old, were randomly assigned, following a 1-wk acclimatization period, to 14 dietary treatment groups of 10 animals. The 14 groups were required to evaluate the importance of three primary variables: 1) varying the dosage of trans fat; 2) examining the effect of trans fat ingested with cholesterol; or 3) examining the effect of trans fat ingested with flaxseed. The third variable was further examined to identify the importance of the ALA and lignan content within flaxseed as a mechanism for any effects of the whole flaxseed. ALA was ingested, or, conversely, a defatted flaxseed chow was ingested that had a depleted ALA content. Secoisolarecinol diglucoside (SDG) was also ingested in isolation.
TestDiet (Richmond, IN) created all of the diets used in this study. The 14 experimental diets consisted of a base of a delipidated RMH3000 diet from TestDiet with the fat content replaced by one of two fat sources at two concentrations: 4 or 8% regular (R) fat (pork/soy) and 4 or 8% trans (T) fat. The source of trans fat used in this study was industrially produced partially hydrogenated vegetable shortening rich in elaidic trans fatty acid (iTFA). The 4 and 8% partially hydrogenated vegetable shortening diets provided 1.4% iTFA and 2.8% iTFA, respectively. The diets were supplemented with either 2% dietary cholesterol (C), whole ground flaxseed (F), or one of the components of flaxseed: flaxseed oil rich in ALA, dietary fiber [partially defatted flaxseed meal (PDFM); P] or the lignan SDG (L). The 14 experimental diets are as follows: 1) 4% regular fat chow (R); 2) 4% trans fat chow (T); 3) 4% trans fat ϩ 10% flaxseed chow (TϩF); 4) 4% trans fat ϩ 4.4% flaxseed oil rich in ALA chow (TϩALA); 5) high (8%) regular fat chow (HR); 6) high (8%) trans fat chow (HT); 7) high (8%) trans fat ϩ 10% flaxseed chow (HTϩF); 8) high (8%) trans fat ϩ 4.4% flaxseed oil rich in ALA chow (HTϩALA); 9) 2% cholesterol ϩ 4% regular fat chow (CϩR); 10) 2% cholesterol ϩ 4% trans fat chow (CϩT); 11) 2% cholesterol ϩ 4% trans fat ϩ 10% flaxseed chow (CϩTϩF); 12) 2% cholesterol ϩ 4% trans fat ϩ 4.4% flaxseed oil rich in ALA chow (CϩTϩALA); 13) 2% cholesterol ϩ 4% trans fat ϩ 7% PDFM chow (CϩTϩP); and 14) 2% cholesterol ϩ 4% trans fat ϩ 0.44% lignan chow (CϩTϩL). Mice were given 4 g of one of the 14 diets per mouse daily. Water was provided ad libitum. The mice were housed in plastic cages (maximum 5 animals per cage) in a room with controlled temperature, humidity, and a 12-h light cycle. Guidelines for the ethical care and treatment of animals from the Canadian Council on Animal Care were strictly followed (30) . Our research protocol was approved by the Animal Review Committee of the University of Manitoba.
Nutritional composition of the experimental diets. The nutritional composition of the experimental diets was analyzed by Industrial Laboratories of Canada in Mississauga, ON, for proximate analysis of crude protein, carbohydrate, fat, fiber, ash, and digestible energy.
Blood and tissue collection and analyses. Following 14 wk of dietary intervention, the mice were deprived of food overnight, anesthetized with pentobarbital sodium (0.35 mmol/kg, intraperitoneally), and killed via cardiac puncture. Serum and plasma were collected and stored at Ϫ80°C until further analysis. Serum total TG and cholesterol levels were quantified using commercial enzymatic kits (Infinity triglycerides 7500 and Infinity cholesterol 7500, Thermo Electron). Total fatty acids were extracted from the plasma samples and derivatized as previously described (5) . Fatty acid methyl esters were analyzed using a Varian CP-3800 gas chromatograph (Mississauga, ON, Canada) equipped with a flame ionization detector and Varian CP-Sil 88 capillary column (100 m ϫ 0.25 mm ϫ 0.20 mm). Components were identified by comparison with authentic standards (Nu-Chek Prep, Elysian, MN). The aorta was excised, cleaned, and evaluated for the extent of atherosclerotic development, as previously described (6) . Atherosclerotic lesion formation was assessed as a percentage (aortic area with developed lesions vs. total luminal surface area ϫ 100).
Statistical analysis. Statistical analysis of data was performed using SigmaStat software (version 2.03, SPSS, Chicago, IL). Data are expressed as means Ϯ SE. Statistical comparisons were made using one-way ANOVA, followed by Fisher's least significant difference post hoc test for multiple parametric comparisons using the Sigma Stat software. In some cases, a Kruskal-Wallis test was used followed by a Student-Newman Keuls post hoc test to identify significant differences. Statistical analyses were carried out on values we obtained, even when they were extremely low. Differences between means were considered significant when P Ͻ 0.05.
RESULTS
Experimental diets. The nutritional composition of the 14 experimental diets is listed in Table 1 . The diets were created Ash, protein, fiber, carbohydrates (CHO), and fat (g/100 g diet) are represented as a percentage of total nutrients, measured by proximate analysis (as fed). Trans fatty acid (TFA) content (g/100 g diet) was estimated based on the addition of 4% partially hydrogenated shortening containing 35% TFA content to the diets. Calories are defined as digestible energy. Caloric content of fat, protein, and CHO constituents in the diet were calculated as 9, 4, and 4 kcal/g. Fiber content of the CHO component was subtracted to yield the total caloric content of CHO. Protein, crude protein; fiber, crude fiber; fat, crude fat; calories, digestible energy (kcal/g).
to test the anti-atherogenic potential of whole ground flaxseed or one of its components: flaxseed oil (ALA), dietary fiber (PDFM), or lignan, in the presence of two atherogenic agents: cholesterol and iTFAs. Three diets containing regular fat (R, HR, and CϩR) and three diets containing iTFAs (T, HT, and CϩT) were created to serve as internal controls for the eight diets containing flaxseed (TϩF, HTϩF, and CϩTϩF) or one of the components of flaxseed (TϩALA, HTϩALA, CϩTϩALA, CϩTϩP, and CϩTϩL). The grain content in each of the diets contributed a small amount of dietary fat. As detailed in Table 1 , doubling the amount of added fat increased the dietary fat content by approximately one-third, and adding cholesterol to the diet added ϳ20% more dietary fat. Adding 10% whole ground flaxseed or 4.4% flaxseed oil (ALA) increased the fat and caloric content compared with their respective control groups. The diets containing PDFM (CϩTϩP) and lignan (CϩTϩL) contained a similar fat content to the diets with cholesterol and iTFAs. The T, TϩF, TϩALA, CϩT, CϩTϩF, CϩTϩALA, CϩTϩP, and CϩTϩL diets contained 1.4% iTFAs, which relates to ϳ3.2% of caloric energy as TFA intake. The HT, HTϩF, and HTϩALA diets contained 2.8% TFA, which provides ϳ6.4% of caloric energy as TFA intake. The ash, protein, fiber, and carbohydrate content of all of the diets were controlled and similar among the groups. Despite an increase in dietary fat in the higher fat groups, the digestible energy levels provided by the diets were all in a similar range (within 3.5 and 3.9 kcal/g). There were no differences in weight gain among the mice in the various groups over the course of the study.
Circulating fatty acid levels. Differences in the plasma fatty acid profile of the mice following the 14-wk feeding period were observed (Fig. 1, Table 2 ). To be as comprehensive as possible, we have reported the effects of the intervention on saturated fatty acids, monounsaturated fatty acids, PUFAs, and TFAs. Supplementing the diet with cholesterol resulted in higher circulating levels of saturated fatty acids (16:0 and 18:0), monounsaturated fatty acids (16:1 and 18:1), and PUFA [18:2(n-6), 18:3(n-3), and 20:5(n-3)] than in the same diets without cholesterol. This rise was partially attenuated by the addition of TFA in the atherogenic diet (CϩT). Consuming TFA in the absence of cholesterol (T and HT diet) did not result in significantly elevated plasma TFA levels. However, the addition of TFA in an atherogenic diet (CϩT) resulted in elevated plasma TFA levels. Circulating levels of elaidic acid (18:1t9) were highest in the CϩT group. The addition of whole ground flaxseed to the atherogenic diet (CϩTϩF) had no impact on the levels of 18:1t6 and elaidic acid, but it increased circulating levels of vaccenic acid (18:1t11). The CϩTϩF diet contained the higher levels of vaccenic acid compared with all other groups. Surprisingly, both of the groups consuming ALA and PDFM (CϩTϩALA and CϩTϩP) had lower levels of elaidic acid than did the CϩT and CϩTϩF groups. In general, circulating ALA (18:3n-3) levels were elevated when flaxseed, ALA, or cholesterol were provided in the diet. The addition of TFA in the diet reduced circulating ALA levels in these groups. Circulating ALA levels were lower in the HϩTϩALA group vs. the TϩALA group and lower in the CϩT vs. CϩR group. The addition of PDFM to the diet prevented the reduction in circulating ALA when TFA are added to an atherogenic diet; however, the addition of lignan did not. Circulating levels of arachidonic acid (20:4n-6) were highest in the groups consuming regular or trans fat or cholesterol (R, T, HR, HT, CϩR, and CϩT). The addition of whole ground flaxseed, ALA, or PDFM to the diet reduced circulating arachidonic acid levels. The addition of lignan to the diet had no impact. Circulating levels of EPA (20:5n-3) were moderately elevated in the CϩR and CϩT groups. The addition of flaxseed or ALA in the diet without any cholesterol supplementation did not significantly elevate EPA levels. However, when provided in the atherogenic diet, only whole ground flaxseed resulted in higher EPA levels than that in the CϩR and CϩT groups. The addition of ALA, PDFM, or lignan did not elevate EPA levels.
Circulating cholesterol and TG levels. As expected, the inclusion of cholesterol in the diet induced a significant increase in serum cholesterol levels ( Fig. 2A) . Serum cholesterol levels were also slightly, but significantly, elevated in the HTϩF group compared with the T group. The addition of either one of the three components of flaxseed, ALA, PDFM, or lignan reduced circulating cholesterol levels compared with that in the CϩR and CϩT groups. Surprisingly, the addition of whole ground flaxseed did not reduce serum cholesterol levels to a significant extent compared with that in the CϩR and CϩT groups. The addition of ALA and PDFM, but not lignan, resulted in significantly lower cholesterol levels than that in the CϩTϩF group.
Serum TG levels were significantly elevated in the groups consuming flaxseed, defatted flaxseed, or ALA, and in the Table 2 . Plasma fatty acids group consuming two atherogenic agents (TϩALA, HTϩF, HTϩALA, CϩTϩF, CϩTϩALA, CϩTϩP, and CϩT) (Fig.  2B) . Serum TG levels were not elevated in the group consuming two atherogenic agents and flaxseed lignan (CϩTϩL). Serum TG levels were higher in the CϩTϩF group compared with all other groups.
Aortic atherosclerotic development. Mice fed a control diet (R) did not exhibit appreciable aortic atherosclerotic plaque formation following 14 wk of dietary intervention (Fig. 3) . Increasing the fat content in the diet resulted in a small but significant increase in atherosclerotic lesions (HR Ͼ R). Replacing the regular fat with a source of iTFAs was accompanied by the development of aortic atherosclerosis, an event not normally observed in the LDLr Ϫ/Ϫ mouse, unless it is fed dietary cholesterol or a strongly atherogenic diet (8) . The iTFAs initiated atherosclerotic development in a dose-dependent manner (T Ͼ R and HT Ͼ HR). These data confirm our laboratory's previous findings (5, 6) . Including whole ground flaxseed or ALA in the diets containing moderate and high doses of iTFAs (TϩF, TϩALA, HTϩF, and HTϩALA) completely prevented atherosclerotic development (Fig. 3) .
Including cholesterol in the diet of the LDLr Ϫ/Ϫ mice induced a significant atherogenic effect. A diet supplemented with 2% cholesterol was chosen based on previous reports that it can reliably induce atherosclerosis in LDLr knockout mice (15, 20) . As previously demonstrated, adding iTFAs in the atherogenic diet did not stimulate atherosclerosis beyond the cholesterol-mediated atherogenic action (6) . Adding whole ground flaxseed to a diet containing both cholesterol and iTFAs (CϩTϩF) partially but significantly inhibited atherosclerotic development. Dietary fiber and lignan had no appreciable effect on atherosclerosis under these conditions. However, adding ALA to the diet significantly inhibited atherosclerotic lesion development. ALA reduced the extent of developed atherosclerotic lesions to similar levels as observed in the groups fed iTFAs or higher doses of fat with no added cholesterol (T, HR, and HT).
DISCUSSION
While it is well established that elevated cholesterol intake is associated with the atherogenic process and the risk of coronary heart disease, the direct association between the intake of iTFA and atherosclerosis has only recently been demonstrated (5, 6). Our laboratory's previous work has demonstrated that iTFAs dose-dependently initiate the atherogenic process (6) . The source and dosage of TFA provided to the mice in this study [as well as our laboratory's previous work (6)] was similar in type and energetic load to previous clinical and experimental reports and to current human TFA consumption values (4, 9, 39) . The diets providing elaidic acid rich, partially hydrogenated vegetable shortening in either a moderate (T) or high (HT) dose, provided 1.4 and 2.8% industrial source TFAs (iTFAs), representing 3.2 and 6.4% of caloric energy, respectively. Estimates of TFA intake range from 0.7-28.7 g·person Ϫ1 ·day Ϫ1 with the average daily trans fat intake in North America reported as 5.8 g or 2.6% of calories (4) . Thus the TFA dosages used in the present investigation are relevant to both the typical as well as a high-TFA consumption levels in humans.
It is important to recognize that other interpretations of the dietary interventions used here are possible. For instance, if one plots the carbohydrate-to-iTFA free fat ratio to the atherogenic index in each of the three group categories, one can conclude that, irrespective of iTFA, the carbohydrate-to-fat ratio in the diet is also an important determinant of atherogenesis. This is consistent with previous results (28) . This does not detract from the importance of iTFAs to the induction of atherosclerosis, but does emphasize the complex multifactorial nature of dietary interventions and their relationship to cardiovascular disease.
Our research is the first to demonstrate that combining an anti-atherogenic dietary agent, such as flaxseed, with iTFAs in the diet protects against the initiation and progression of atherosclerotic development. This finding is particularly pertinent as the LDLr Ϫ/Ϫ mouse is considered an excellent model of human atherosclerotic disease (8) . Furthermore, our study demonstrates that both whole ground flaxseed and an ALA-rich flaxseed oil completely prevented the initiation of atherosclerotic development induced by the consumption of a moderate or high dose of iTFAs (Fig. 3) . Because the ALA and whole ground flaxseed afforded similar beneficial effects, it is reasonable to conclude that the ALA-rich fraction was responsible for the majority of the cardioprotective effects of flaxseed. This conclusion would be consistent with other studies investigating the effects of ALA on cardiovascular disease. Epidemiological, randomized clinical trials and experimental investigations suggest that ALA may be anti-atherogenic via a host of cardioprotective actions (15, 16, 37, 43, 45) . It has been suggested to reduce circulating cholesterol levels; it may act as an antiinflammatory, anti-aggregatory, hypotensive, and anti-arrhythmic agent; and it can inhibit the proliferative processes that occur in cells found in the atherosclerotic vessel wall (1, 2, 10, 15, 16, 31, 37, 43, 45) .
The protective effects of ALA extend beyond inhibiting the initiation of atherosclerosis caused by iTFAs alone. We have demonstrated that dietary ALA from flaxseed offers preventative benefits in the presence of two atherogenic risk factors (cholesterol and iTFAs). The PDFM poor in ALA and the lignan SDG provided little protection against atherosclerotic development induced by feeding cholesterol and iTFAs, further confirming that the ALA rich content of dietary flaxseed is the component responsible for the beneficial actions. SDG was chosen as the lignan component within flaxseed that should be studied because it is 1) the primary lignan found in flaxseed; and 2) because Prasad and colleagues (33-36) have shown it possesses anti-atherogenic properties. Its lack of anti-atherogenic action in the present study may represent a difference in animal species used in previous studies (33) (34) (35) (36) .
The protective effect of ALA in the present study appears to be independent of changes in circulating cholesterol and TG levels. Whole ground flaxseed and the ALA did not lower circulating lipid levels in the absence of dietary cholesterol, and even exacerbated the cholesterol levels in the HTϩF and TGs in the T and HT groups, yet they were able to abolish atherosclerotic development induced by iTFAs, suggesting that flaxseed offers an anti-atherogenic protection via a mechanism other than a lipid-lowering effect. All of the flaxseed fractions (oil, fiber, and lignan) offered a lipid-lowering effect in the presence of cholesterol compared with their respective control diet (CϩT) in the presence of two atherogenic agents. Whole ground flaxseed did not. However, only whole ground flaxseed and ALA limited the development of advanced atherosclerotic lesions in the presence of the two atherogenic risk factors, further suggesting that the anti-atherogenic effects of flaxseed are independent of a lipid-lowering effect. A systematic review of 14 studies concluded that ALA had little effect on circulating lipids (46) .
In our study, the group consuming flaxseed in the presence of two atherogenic agents had the highest circulating lipid levels. Although the reason for the elevated TG levels in this group is unknown, it cannot be solely attributed to the higher fat content of the CϩTϩF diet, as it contained a similar fat content as the other diets containing flaxseed (TϩF, TϩALA, HTϩF, HTϩALA, and CϩTϩALA). Surprisingly, the addition of the lignan fraction reduced circulating TG levels better than whole ground flaxseed. This effect on circulating TG levels may partly explain its anti-atherogenic action in other models (33) (34) (35) (36) . It is important to acknowledge that flaxseed significantly increased TGs in the CϩT group (CϩTϩF), despite reducing atherogenic lesions. In human trials, there is some controversy regarding the effects of flaxseed on circulating TG levels (38, 46) . It would appear that a consensus response has not been identified as of yet.
The effects of a trans fat-enriched diet on circulating fatty acid levels was interesting as well. Generally, the trans fat diet had no effect on circulating saturated or monounsaturated fats. In the presence of dietary supplementation with cholesterol, these fats actually decreased. Conversely, the trans fat-enriched diet elevated the levels of -3 PUFAs, but decreased the n-6 PUFAs. This was particularly evident with respect to the n-6 fatty acid species arachidonic acid and linoleic acid. This is clearly related to the interconversion of the n-3 and n-6 metabolic pathways (38) . The ability of dietary cholesterol to enhance the bioavailability of TFAs is also noteworthy and intensifies the concerns about the potentially significant consequences of poor dietary habits.
Despite warnings and legislation to reduce TFA content in foods (3, 18, 23, 29) , it may be impossible to completely avoid the ingestion of TFAs in today's society. Identifying foods that may reduce the cardiotoxic actions of TFAs, therefore, will be important information. It is apparent that adding whole ground flaxseed or flaxseed oil to the typical Western diet containing TFAs and cholesterol offers an effective dietary strategy to protect against atherosclerotic cardiovascular disease. 
